The company laid out a plan to look beyond obesity and diabetes. Investors heard growth guidance that merely matches its rivals, and sold the stock anyway.
Novo Nordisk shares fell nearly 8% this week, their worst trading day since February, after the company's Capital Markets Day failed to deliver the kind of aggressive turnaround plan investors had been hoping for as the exclusivity clock on its flagship obesity drug's active ingredient starts ticking toward the early 2030s.
The company outlined plans to launch more than five "multi-blockbuster" drugs by 2030, targeting over 150 billion Danish kroner, roughly $23 billion, in sales by 2035, with revenue growth guided in line with a broad group of industry peers including Eli Lilly, AstraZeneca, Amgen, Biogen, Merck, AbbVie and Novartis. For a company whose stock has fallen 34% over the past year while chief rival Eli Lilly's has risen more than 54%, "in line with peers" was not the answer the market was looking for.
Chief Executive Mike Doustdar acknowledged the gap between the plan and its reception directly. "I think yesterday we laid out a more clear strategy of the direction we want to take the company at. We talked about diversification of the company, but yet the reaction tells me that there's still some work to do in convincing some of the investors," he said. Asked about acquisitions, Doustdar signaled Novo is actively looking outside its traditional core: "Let's see where the gaps are, and let's go out and see who has produced or is about to introduce better drugs than we are able to do on our own, and when that gap can be filled with M&A, we are actually quite interested about it."
The diversification plan itself points beyond diabetes and obesity into blood and endocrine disorders, liver disease and cardiovascular disease, areas Novo describes as adjacent to its existing expertise rather than entirely new territory. Doustdar said future dealmaking is more likely to happen outside the company's historical core areas than within them.
The competitive backdrop makes the muted response easier to understand. Eli Lilly has captured a large share of the weight-loss market with its Zepbound and Mounjaro injectables despite launching years after Novo's Wegovy, and Lilly Chief Executive David Ricks said this week that a third of new patients starting on the company's GLP-1 drugs are now choosing its oral pill, Foundayo, over injectable options. With Wegovy's active ingredient facing exclusivity loss in the early 2030s, investors appear to be waiting for evidence that Novo's diversification plan can actually outrun that clock, not simply keep pace with it.